Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerofe in Advanced MDS and AML
NCT04365179Phase 1Recruiting
- Sponsor
- Immune System Key Ltd.
- Start
- Jun 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nerofe in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Immune System Key Ltd. Primary endpoints: Change in IWG Criteria to evaluate response to Nerofe Treatment for MDS patients, Change in IWG Criteria to evaluate response to Nerofe Treatment for MDS patients (Frequent Monitoring) and 3 more. Started Jun 2020; status: recruiting.
02
Drugs
nerofe
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04365179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365179.